ATE525083T1 - Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung - Google Patents

Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung

Info

Publication number: ATE525083T1
Authority: AT; Austria
Prior art keywords: pharmaceutical composition; asp; insulin; analog; active compound
Prior art date: 2003-11-13

Application number

AT04797450T

Other languages

English (en)

Inventor

Liselotte Bjerre Knudsen

Kristian Tage Hansen

Dorthe Kot Engelund

Svend Ludvigsen

Lars Hansen

Claude Bonde

Ejvind Jensen

Tine Elisabeth Gottschalk Boving

Morten Schlein

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-13

Filing date

2004-11-12

Publication date

2011-10-15

2004-11-12 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2011-10-15 Application granted granted Critical

2011-10-15 Publication of ATE525083T1 publication Critical patent/ATE525083T1/de

Links

108090001061 Insulin Proteins 0.000 title abstract 2
230000002473 insulinotropic effect Effects 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title 2
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
102000004877 Insulin Human genes 0.000 title 1
229940125396 insulin Drugs 0.000 title 1
239000004094 surface-active agent Substances 0.000 title 1
235000012054 meals Nutrition 0.000 abstract 1
238000007911 parenteral administration Methods 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Endocrinology (AREA)
Veterinary Medicine (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Emergency Medicine (AREA)
Biophysics (AREA)
Immunology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)

AT04797450T 2003-11-13 2004-11-12 Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung ATE525083T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200301689		2003-11-13
PCT/DK2004/000788 WO2005046716A1 (en)	2003-11-13	2004-11-12	Soluble pharmaceutical compositions for parenteral administration comprising a glp-1 peptide and a insulin peptide of short time action for treatment of diabetes and bulimia

Publications (1)

Publication Number	Publication Date
ATE525083T1 true ATE525083T1 (de)	2011-10-15

Family

ID=34585770

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04797450T ATE525083T1 (de)	2003-11-13	2004-11-12	Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung

Country Status (5)

Country	Link
EP (1)	EP1684793B1 (de)
JP (1)	JP4800959B2 (de)
AT (1)	ATE525083T1 (de)
ES (1)	ES2373660T3 (de)
WO (1)	WO2005046716A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003002136A2 (en)	2001-06-28	2003-01-09	Novo Nordisk A/S	Stable formulation of modified glp-1
EP1617888B1 (de)	2003-04-23	2019-06-12	Valeritas, Inc.	Hydraulisch aktivierte pumpe für langzeitabgabe von medikamenten
KR101308912B1 (ko)	2003-06-03	2013-09-23	노보 노르디스크 에이/에스	안정화된 약학적 펩티드 조성물
PL1633391T3 (pl)	2003-06-03	2012-03-30	Novo Nordisk As	Stabilizowane farmaceutycznie kompozycje peptydowe
DK3300721T4 (da) *	2003-11-20	2025-03-03	Novo Nordisk As	Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
EP2298337B1 (de) *	2003-12-09	2017-02-22	Novo Nordisk A/S	Regulierung des bevorzuchtes nahrungsaufnahmen mit verwendung von GLP-1 agonisten
WO2006014425A1 (en)	2004-07-02	2006-02-09	Biovalve Technologies, Inc.	Methods and devices for delivering glp-1 and uses thereof
PL1789434T3 (pl)	2004-08-31	2014-07-31	Novo Nordisk As	Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
WO2006051103A2 (en) *	2004-11-12	2006-05-18	Novo Nordisk A/S	Stable formulations of peptides
MX2007005521A (es) *	2004-11-12	2007-05-18	Novo Nordisk As	Formulaciones estables de peptidos insulinotropicos.
KR101361376B1 (ko)	2006-03-30	2014-02-10	발레리타스 인코포레이티드	복합-카트리지 유체 전달 장치
WO2008023050A1 (en)	2006-08-25	2008-02-28	Novo Nordisk A/S	Acylated exendin-4 compounds
BRPI0820535B8 (pt)	2007-11-16	2021-05-25	Novo Nordisk As	composições farmacêuticas contendo insulina e um peptídeo insulinotrópico
JP2011506442A (ja) *	2007-12-11	2011-03-03	コンジュケムバイオテクノロジーズインコーポレイテッド	インスリン分泌性ペプチド結合体の製剤
MY152979A (en)	2008-01-09	2014-12-15	Sanofi Aventis Deutschland	Novel insulin derivatives having an extremely delayed time-action profile
RS59913B1 (sr) *	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
CN102596175A (zh)	2009-07-06	2012-07-18	赛诺菲-安万特德国有限公司	含有甲硫氨酸的水性胰岛素制备物
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
CA2786953A1 (en) *	2010-01-12	2011-07-21	Florian Anders Foeger	Pharmaceutical compositions for oral administration of insulin peptides
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AR092862A1 (es)	2012-07-25	2015-05-06	Hanmi Pharm Ind Co Ltd	Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en)	2012-12-21	2017-11-23	Sanofi	Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
TWI780236B (zh)	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
EP3080154B1 (de)	2013-12-13	2018-02-07	Sanofi	Duale glp-1/gip-rezeptoragonisten
EP3080152A1 (de)	2013-12-13	2016-10-19	Sanofi	Nicht-acylierte exendin-4-peptidanaloga
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
MX2016008979A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
MX2016008978A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
BR112016015851A2 (pt)	2014-01-09	2017-08-08	Sanofi Sa	Formulações farmacêuticas estabilizadas de insulina aspart
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
EP3229828B1 (de)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Insulin-glargin/lixisenatid-fixierte verhältnisformulierung
TW201630622A (zh) *	2014-12-16	2016-09-01	美國禮來大藥廠	速效胰島素組合物
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
GB201607918D0 (en)	2016-05-06	2016-06-22	Arecor Ltd	Novel formulations
KR102665710B1 (ko)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	Glp-1 조성물 및 그 용도
SG11202111311WA (en)	2019-06-14	2021-12-30	Zealand Pharma As	Pharmaceutical parenteral composition of dual glp1/2 agonist
JP7761567B2 (ja)	2020-02-18	2025-10-28	ノヴォノルディスクアー／エス	医薬製剤
CA3200526A1 (en) *	2020-12-16	2022-06-23	Jesper Skodborg VILLADSEN	Pharmaceutical composition of glp-1/glp-2 dual agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH25772A (en) *	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
IL93282A (en) *	1989-02-09	1995-08-31	Lilly Co Eli	Insulin analogues
US5514646A (en) *	1989-02-09	1996-05-07	Chance; Ronald E.	Insulin analogs modified at position 29 of the B chain
IL128332A0 (en) *	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
US6458924B2 (en) *	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
EP0929576A1 (de) *	1996-08-30	1999-07-21	Novo Nordisk A/S	Glp-2 derivate
DE122007000044I2 (de) *	1997-01-07	2011-05-05	Amylin Pharmaceuticals Inc	Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
WO2001000223A2 (en) *	1999-06-25	2001-01-04	Minimed Inc.	Multiple agent diabetes therapy
EP1076066A1 (de) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptide zur Senkung des Blutglukosespiegels
WO2001051071A2 (en) *	2000-01-11	2001-07-19	Novo Nordisk A/S	Transepithelial delivery of glp-1 derivatives
EP1432430A4 (de) *	2001-08-28	2006-05-10	Lilly Co Eli	Vormischungen von glp-1 und basalinsulin

2004
- 2004-11-12 ES ES04797450T patent/ES2373660T3/es not_active Expired - Lifetime
- 2004-11-12 JP JP2006538658A patent/JP4800959B2/ja not_active Expired - Fee Related
- 2004-11-12 EP EP04797450A patent/EP1684793B1/de not_active Expired - Lifetime
- 2004-11-12 AT AT04797450T patent/ATE525083T1/de not_active IP Right Cessation
- 2004-11-12 WO PCT/DK2004/000788 patent/WO2005046716A1/en not_active Ceased

Also Published As

Publication number	Publication date
WO2005046716A1 (en)	2005-05-26
ES2373660T3 (es)	2012-02-07
JP2007510675A (ja)	2007-04-26
JP4800959B2 (ja)	2011-10-26
EP1684793A1 (de)	2006-08-02
EP1684793B1 (de)	2011-09-21

Legal Events

Date	Code	Title	Description
2012-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE525083T1 (de)	2011-10-15	Pharmazeutische zusammensetzung umfassend eine insulinotrope glp-1(7-37) analoge, asp(b28)- insulin, und eine oberflächenaktive verbindung
WO2006051103A3 (en)	2006-11-16	Stable formulations of peptides
DK1143989T3 (da)	2007-04-16	Exendiner til glucagonundertrykkelse
ZA200606153B (en)	2007-12-27	Intranasal administration of glucose-regulating peptides
WO2009063072A3 (en)	2010-01-07	Pharmaceutical compositions comprising glp-1 peptides or exendin-4 and a basal insulin peptide
AU2003243750A1 (en)	2004-01-06	Rapidly dissolving micro-perforator for drug delivery and other applications
WO2006051110A3 (en)	2006-11-02	Stable formulations of insulinoptropic peptides
WO2006097536A3 (en)	2006-12-28	Dimeric peptide agonists of the glp-1 receptor
AU2003234529A1 (en)	2003-12-12	Glp-1 gene delivery for the treatment of type 2 diabetes
ATE412387T1 (de)	2008-11-15	Medizinische vorrichtungen
CL2009001899A1 (es)	2010-02-12	Composicion farmaceutica que comprende: i) un antagonista del receptor de at1 o una sal, ii) un sensibilizante a la insulina o una sal y iii) un vehiculo farmaceuticamente aceptable; uso para la prevencion, demora de progreso o tratamiento de hipertension, diabetes, entre otras (div. sol. 2034-01).
AU2003295614A8 (en)	2004-06-23	Delivery of pharmaceutical agents via the human insulin receptor
TNSN03116A1 (en)	2005-12-23	Pulmonary administration of chemically modified insulin
MX2007004769A (es)	2007-06-25	Derivado de pirimidina condensado con un anillo no aromatico.
MX2023014771A (es)	2024-03-19	Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
CY1113755T1 (el)	2016-07-27	Η λιξισενατιδη ως επιπροσθετη αγωγη στην ινσουλινη γλαργινη και στη μετφορμινη για τη θεραπευτικη αντιμετωπιση του διαβητη τυπου 2
AU2003279253A1 (en)	2004-01-06	Silicone blends and composites for drug delivery
ATE354362T1 (de)	2007-03-15	Stabilisierte pharmazeutische zusammensetzung enthaltend einen amorphen wirkstoff
AU2003220956A1 (en)	2003-10-20	Insulin administration apparatus
EA200702116A1 (ru)	2008-02-28	Фармацевтическая дозированная форма (варианты) с контролируемым высвобождением антигипергликемического средства в комбинации с производным тиазолидиндиона
Youn et al.	2008	Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation
CA3251240A1 (en)	2023-08-10	DUAL GLP-1 AND GLUCAGON AGONIST PEPTIDES WITH IMPROVED BIOLOGICAL STABILITY
PL1609481T3 (pl)	2008-02-29	Nadająca się do wstrzykiwania kompozycja farmaceutyczna zawierająca diklofenak sodowy, beta-cyklodekstrynę i polisorbat
EP1110568A3 (de)	2002-11-27	Medikamenteninfusionsspritze
AR012996A1 (es)	2000-11-22	Uso de un sensibilizador a la insulina para la preparacion de un medicamento y composicion farmaceutica que comprende dicho sensibilizador.